Within acutely demyelinated MS plaques paucity of NCAM immunostaining has been demonstrated (Massaro et al. 1987), in addition to low levels of circulating NCAM in the CSF, and differential expression of NCAM in active and chronic MS lesions have been identified by proteomics (Han et al. 2008). This evidence concerns the gene NCAM1 and myeloid sarcoma.